DNA-testing service 23andMe is making substantial efforts to nurse its feeble genetic core back to health. The company will lay off 40% of its workforce, over 200 employees, and cull its therapy programs that include cancer-treatment research, part of a massive restructuring plan announced Monday.
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,” CEO Anne Wojcicki said in a statement.
